The Biology and Clinical Management of CML

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1042047

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Chronic myeloid leukaemia was almost always fatal before the development of imatinib a decade ago, the first tyrosine kinase inhibitor (TKI) developed to treat a human cancer. There are now more potent TKIs that are effective in cases of resistance to imatinib. The challenge now is to optimise the achievement of remissions using these drugs and convert CML into a curable condition. This will be the focus of my NHMRC Practitioner Fellowship over the next 5 years.

Funded Activity Details

Start Date: 01-01-2013

End Date: 01-01-2017

Funding Scheme: Practitioner Fellowships

Funding Amount: $480,243.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Molecular Targets

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

cancer research | chronic myeloid leukaemia (CML) | clinical trial | kinase inhibitors | leukaemia | oncogenes | targeted therapy

Related Links